INTRODUCTION

The opioid epidemic in the United States (US) continues to be a major public health crisis, claiming lives at an alarming rate. In 2019 there were more than 70,000 drug overdose deaths in the US. Of these fatalities, nearly 70% involved opioids. In 2020 overall drug overdose mortality increased by nearly 30% from 2019. In addition to the substantial human toll of the opioid epidemic, the associated healthcare, criminal justice, and other societal costs were estimated to be almost $820 billion in 2019. The economic and human loss is devastating in light of available Food and Drug Administration-approved, evidence-based medications for opioid use disorder (MOUD), including buprenorphine and methadone. However, over 70% of patients with opioid use disorder (OUD) are not receiving these treatments.

The emergency department (ED) remains the safety net and point of entry into the healthcare system for many patients struggling with substance use disorders (SUD). Visits to the ED for opioid overdoses continue to increase. Between 1999–2012, opioid-related encounters in US EDs increased by 170%.
Mortality rates after ED visits for nonfatal opioid overdoses are high; greater than 5% of patients die within one year, with the highest risk period being the first month post-overdose. As the ED is often the only point of entry into the healthcare system for patients with OUD, there is a tremendous opportunity to reduce treatment gaps through ED-based MOUD initiation and early referral to long-term treatment.

Buprenorphine and methadone are both evidence-based treatments for OUD that effectively treat opioid withdrawal symptoms, decrease illicit opioid use, and reduce opioid overdose-related mortality. Buprenorphine, a partial μ-opioid agonist with high receptor affinity, is the most common form of MOUD used to initiate treatment in the ED. Buprenorphine initiation in the ED and referral to outpatient treatment has been shown to be safe and effective, with increased addiction-treatment engagement at 30 days after discharge compared to brief intervention with referral or referral-only interventions. Although adoption of this practice has been slow, recently published surveys found substantial support for ED-initiated buprenorphine among emergency physicians (EP). Likewise, the American College of Emergency Physicians (ACEP) and the American Academy of Emergency Medicine published position statements recommending that EPs initiate patients on buprenorphine in the ED and offer linkage to outpatient follow-up treatment.

Methadone, a full μ-opioid agonist, is the most studied MOUD and has been used for over 50 years to treat OUD. The number of facilities offering buprenorphine increased by an average of 9% annually between 2009–2018, while the number of facilities that offered methadone only increased by an average of 2% per year. Although methadone is associated with higher treatment retention rates than buprenorphine, methadone carries a considerable social stigma among clinicians because patients treated with methadone are perceived to be more medically complex and therefore difficult to treat. In addition to stigma, access to methadone is more difficult because it must be obtained daily and in person at an opioid treatment program (OTP), while buprenorphine can be prescribed in an office-based setting by an X-waivered physician.

Whereas ED-based buprenorphine initiation with long-term treatment linkage has been previously described, data is lacking on methadone initiation in the ED. To date, there is only one study evaluating low-dose intramuscular administration of methadone to treat opioid withdrawal syndrome in the ED. While buprenorphine is more commonly initiated in the ED, methadone is a life-saving alternative treatment option that may be preferred by patients who have not been successful with buprenorphine in managing their OUD. Creating more opportunities and pathways for initiation of multiple effective forms of MOUD in the ED and subsequent outpatient treatment linkage may lead to improved treatment retention, as well as decreased morbidity and mortality associated with ongoing opioid use. Thus, it is vital to get EPs’ perspectives on ED-based methadone initiation for patients with OUD.

The purpose of this study was to better understand the attitudes of EPs on offering methadone compared to buprenorphine to patients with OUD in the ED. We tested the hypothesis that EP survey respondents would express preferences for buprenorphine over methadone.

METHODS
Overview

We conducted a cross-sectional survey of EPs to quantify their opinions, using a five-point Likert scale, regarding the prescribing of buprenorphine and the dosing of methadone in the ED. We did this by creating a survey based on similar work that measured EPs’ willingness to initiate buprenorphine in the ED. We sent our survey via email to all members of the ACEP Emergency Medicine Practice Research Network (EMPRN), which during the past several years has had approximately 700 to 1200 members. Our institutional review board approved this study and waived informed consent.

Subjects

Members of ACEP EMPRN are board-certified EPs who represent a cross-section of EPs in the US. Members of EMPRN are asked to participate in surveys distributed via email several times per year.
Data Collection

The survey was initially emailed to ACEP EMPRN members in early March 2021. Reminder emails to complete the survey were subsequently sent in late March and April 2021. Participation in surveys was voluntary and respondents were not required to answer all questions. Data was collected and stored in the secure ACEP member communication and management platform. To avoid social desirability bias, all participants were given a unique participant ID, and survey results were de-identified prior to being returned to the investigators.

Survey

Our survey instrument was based on a previously published survey describing physician attitudes on buprenorphine induction in the ED. We adapted questions specifically focusing on MOUD and excluded any questions about non-opioid treatment of withdrawal symptoms or emergency naloxone prescribing at discharge. We also added a question about referring patients to outpatient clinics that provide MOUD as it applied to the role of the emergency clinician in addressing opioid use. Additionally, the original survey did not include questions on methadone initiation in the ED, and so these were added to the instrument. We collected basic demographics, including primary practice location (urban, rural, or suburban), primary practice region (Northeast, South, Midwest, West), type of healthcare system (community, academic, or federal government hospital), and years out of training. Additionally, we asked whether the first place had obtained their X-waiver, whether they had ever ordered buprenorphine or methadone while working in the ED, and whether their department offered a “warm handoff” or a bridge program to outpatient treatment at discharge for ongoing methadone or buprenorphine treatment.

To compare EPs’ attitudes between buprenorphine and methadone, we asked the same perception questions about both forms of MOUD on a five-point Likert scale. Then we asked respondents to rank perceived barriers to prescribing buprenorphine or dosing methadone in the ED. To prevent participants from completing the survey multiple times, each member of EMPRN and their email addresses were assigned a unique participant ID. If there were multiple entries under the same ID, this was reflected in the data received from EMPRN. Additionally, before every reminder email, the mailing list was edited to reflect who had already responded, and the reminder email was only sent to members who had not responded.

The survey instrument is provided in the “Supplementary Materials” section under Appendix.

Data Analysis

We used descriptive analysis to summarize response frequency and percentage as well as compare responses between buprenorphine and methadone. Using chi-square tests, we evaluated responses to questions about whether the physician had ever ordered buprenorphine or methadone while working in the ED, had obtained X-waiver training, and whether their department offered a “warm handoff” or a bridge program to outpatient treatment at discharge based on primary practice location. The frequency of the ranked barriers to prescribing buprenorphine or dosing methadone in the ED was descriptively compared. Lastly, we grouped participants based on the presence of a warm handoff or bridge program and measured the likelihood of prescribing either MOUD as well as the highest perceived barriers to prescribing buprenorphine and dosing methadone using chi-square testing.

The response rate was calculated using the number of unique emails in the EMPRN database and the number of physicians who either partially or completely finished the survey. Respondents were not required to answer each question to participate in this study. Therefore, we are reporting the number of survey responses generated for each question. Since this is a descriptive study, a sample size was not needed to determine statistical significance.

RESULTS

A total of 141 EPs either completed all or some of the survey, with a response rate of 18.4% (141/765). The majority of participants were male (80.9%), White (82.5%), and had a mean age of about 53 years (Table 1). Thirty-four percent of respondents were located in the southern US. The largest group of participants reported their primary practice location as urban (44.3%), and the majority were practicing within a community setting (63.8%).

The majority of EPs reported ordering either buprenorphine, methadone, or both buprenorphine and methadone (69.5%) while working in the ED (Table 1). Further, about 38% of respondents reported having obtained their X-waiver to prescribe buprenorphine. The majority of participants (57.4%) reported that their department did not offer a “warm handoff” or a bridge program to outpatient treatment at discharge for ongoing methadone or buprenorphine treatment.

Overall, participants had more favorable opinions of using buprenorphine to treat OUD in the ED than methadone. The majority of participants (75%) strongly or somewhat agreed that emergency clinicians should offer buprenorphine to help control the symptoms of opioid withdrawal and craving (Figure 1). In contrast, only about 28% of respondents strongly or somewhat agreed that EPs should offer methadone. This pattern continued, as 95% of participants strongly or somewhat agreed that they would refer patients with OUD to a clinic that provides buprenorphine, but only 63.6% strongly or somewhat agreed that they would refer patients to a methadone clinic. While nearly 88% of respondents stated that they strongly or somewhat agreed with the statement “If my ED had a structured program, I would be comfortable starting buprenorphine for patients who are continuing it after discharge for the purpose of entering treatment,” only about 45% of respondents strongly or somewhat agreed when asked...
buprenorphine or methadone, 34% and 46.1% strongly agreed, respectively (Figure 1). Lastly, 41% of physicians strongly or somewhat agreed with the statement, “Initiating patients on methadone is not within the scope of an [EP’s] practice.”

There was a statistically significant difference between primary practice location and whether EPs had ever ordered either MOUD (P<0.05). There was not a statistically significant difference between primary practice location and whether the physician’s ED offered a “warm handoff” or bridge program to outpatient buprenorphine or methadone treatment at discharge (P = 0.15), or whether the physician had completed X-waiver training (P = 0.08) (Table 2).

Emergency physicians reported similar barriers to treating patients in the ED with either buprenorphine or methadone. The two most frequently reported barriers to treating patients with either MOUD were “I don’t have access to providers for follow-up in my area,” and “I don’t have social work resources for screening and follow-up” (Figure 2). Also of note, the responses, “There’s no financial incentive for my department” and “There is no reimbursement for me” were both infrequently reported as barriers to treating with either buprenorphine or methadone.

Next, we grouped participants on whether they had a bridge for either MOUD and measured the highest perceived barriers to prescribing buprenorphine and dosing methadone. One physician reported having a bridge program set up for only methadone dosing. We found that lack of social work resources for screening was a statistically significant barrier for physicians who did not have a bridge for either MOUD (Table 3). For physicians who lacked a bridge, another significant barrier to prescribing buprenorphine was not having buprenorphine in their ED. Physicians with no bridge program reported that their highest perceived barrier to dosing methadone in the ED was lack of training and not having access to OUD experts for follow-up in their area. We also found that having a bridge present in the physician’s ED facilitated the prescribing of MOUD (Table 3).

**DISCUSSION**

This study compared EPs’ perceptions of using buprenorphine and methadone in the ED and barriers to the use of these medications to treat OUD in the ED. Overall, this study suggests that EPs prefer to use buprenorphine over methadone. Further, although EPs had a more favorable view of using buprenorphine in the ED than methadone, the most significant barriers to using these medications were similar. In this study, 75% of EPs strongly or somewhat agreed that buprenorphine was an appropriate treatment for opioid withdrawal and craving, while only 28% agreed that methadone was an appropriate treatment. When considering ED referrals, 95% of EPs strongly or somewhat agreed that they would be willing to refer patients to a clinic offering buprenorphine. Only 64% strongly or somewhat agreed that they would refer to a methadone clinic. Even when presented
with a structured program for follow-up, only 45% of EPs somewhat or strongly agreed that they felt comfortable initiating methadone in the ED compared to 88% for buprenorphine. Additionally, 41% of physicians did not feel that initiating methadone fell within their scope of practice.

When we grouped our sample by whether a physician had a bridge or not, the highest barrier to prescribing buprenorphine or dosing methadone was a lack of social work resources for screening. Additionally, we found that having a bridge in place helped facilitate the use of MOUD. Both findings are consistent with the literature that states when an ED’s MOUD program includes a follow-up protocol (which could include social workers), physicians feel more comfortable using MOUD to treat OUD in the ED.23

Buprenorphine initiation in the ED increases engagement in treatment, decreases illicit opioid use, and has shown to reduce healthcare-related costs due to SUDs.24 Long-term outcomes for patients receiving either buprenorphine or methadone include reductions in mortality, opioid use, and opioid-related, acute care utilization.9,10,25 The expansive literature supporting methadone treatment suggests that it may lead to similar, if not better, outcomes than buprenorphine for patients struggling with OUD.11,25 In contrast to buprenorphine, methadone offers the significant advantage

Figure 1. Perceptions questions on buprenorphine and methadone.
that the patient does not need to experience withdrawal prior to initiation of treatment.\textsuperscript{26,27} Drawbacks to ED methadone initiation include its complex pharmacology and adverse effect profile. Rapid initiation can lead to central nervous system depression and respiratory compromise, multiple drug-drug interactions exist, and QTc prolongation has been associated with fatal cardiac events.\textsuperscript{18} The safety profile is better for buprenorphine than methadone, but a single, low dose of methadone 20-40 milligrams is often sufficient to treat opioid withdrawal symptoms with few risks.\textsuperscript{12,18}

Although methadone has been the mainstay of OUD treatment since the 1970s, ED initiation and treatment have not been incorporated into common practice for OUD, despite clear evidence of efficacy.\textsuperscript{28} Since the ED will continue to

| MOUD experiences                           | N  | Rural   | Suburban | Urban   | P-value |
|-------------------------------------------|----|---------|----------|---------|---------|
| Ordered MOUD in ED                        |    |         |          |         |         |
| Buprenorphine                             | 25 | 53      |          | 62      |         |
| Methadone                                 | 2  | (8.0)   | 11 (20.8)| 7 (11.3)|         |
| Both                                      | 5  | (20.0)  | 18 (34.0)| 32 (51.6)| 0.002   |
| Neither*                                  | 15 | (60.0)  | 11 (20.8)| 17 (27.4)|         |
| Completed X-waiver                        |    |         |          |         | 0.080   |
| Yes                                       | 5  | (20.0)  | 20 (37.7)| 28 (46.0)|         |
| Department has warm handoff or bridge program to MOUD outpatient treatment |    |         |          |         |         |
| Yes, for buprenorphine                    | 4  | (16.0)  | 17 (32.1)| 24 (38.7)|         |
| Yes, for methadone                        | 0  | (0.0)   | 0 (0)    | 1 (1.6) | 0.152   |
| Yes, for both                             | 1  | (4.0)   | 4 (7.5)  | 8 (12.9)|         |
| No                                        | 20 | (80.0)  | 32 (60.4)| 29 (46.8)|         |

*Neither* was not an option on the survey.
**All questions were not required to be answered to participate in this study.

MOUD, medication for opioid use disorder; ED, emergency department.

Table 2. Experiences with prescribing medications for opioid use disorder vs primary practice location.

Figure 2. Highest perceived barrier by frequency for prescribing methadone or buprenorphine.

MOUD, medication for opioid use disorder; ED, emergency department.

Western Journal of Emergency Medicine 6 Articles in Press
serve as a critical access point for patients with OUD, adding methadone to an emergency clinician’s toolkit to treat OUD may present a valuable opportunity to reduce treatment gaps through MOUD initiation and subsequent referral to treatment. Inclusion of methadone as a treatment option is particularly critical as the country continues to grapple with a surge in high potency synthetic opioid (HPSO) use, including fentanyl and fentanyl analogs. Patients using HPSOs have an increased risk of precipitated withdrawal during buprenorphine induction, thus creating a major barrier to buprenorphine initiation. Therefore, methadone will increasingly need to be considered as part of the treatment algorithm for those dependent on HPSOs.

Two recent studies reported that lack of familiarity with induction methods in the ED and time constraints were significant barriers to buprenorphine induction in the ED. This was not consistent with our study, which found that the main barriers to using either MOUD were a lack of access to follow-up addiction experts or social worker resources. The reason for this difference may be a result of both state and national education programs on buprenorphine utilization, as well as professional organization position statements, which led to the rapid acceptance and uptake of buprenorphine in the ED over the past few years. Emergency departments have worked to create community relationships with clinics that offer buprenorphine and these same relationships can be cultivated with local methadone clinics. Linkage to methadone clinics has been successful in the past when vouchers for methadone treatment were provided to patients discharged from the ED.

Furthermore, published best practices for adopting buprenorphine programs in the ED can be adapted to facilitate ED-based methadone initiation. Examples include using a clinician champion to train colleagues and address administrative barriers and a trained substance-use patient navigator to facilitate linkage to outpatient methadone treatment and assist patients with social determinants of health-related barriers to long-term treatment engagement.

### Table 3. Highest perceived barrier and experience with medications for opioid use disorder by access to a bridge.

|                      | Has bridge | No bridge | P-value |
|----------------------|------------|-----------|---------|
| **Highest ranked barriers for prescribing buprenorphine** |            |           |         |
| There is no reimbursement for me. | N=53, n=2(3.8) | N=76, n=2(2.6) | 1.000 |
| I don’t have access to providers for follow up in my area. | N=53, n=9(17.0) | N=78, n=14(17.9) | 0.886 |
| There’s no financial incentive for my department. | N=52, n=3(5.8) | N=76, n=5(6.6) | 1.000 |
| It takes too much of my time. | N=53, n=8(15.1) | N=78, n=7(9.0) | 0.280 |
| I don’t have social work resources for screening and follow up. | N=54, n=4(7.4) | N=77, n=21(27.3) | 0.004 |
| I don’t have training. | N=53, n=3(5.7) | N=77, n=12(15.6) | 0.082 |
| I don’t have buprenorphine in my ED. | N=52, n=4(7.7) | N=79, n=18(22.8) | 0.024 |
| I don’t want to assume medicolegal risk. | N=54, n=1(1.9) | N=78, n=6(7.7) | 0.239 |
| **Highest ranked barriers for dosing methadone** |            |           |         |
| There is no reimbursement for me. | N=53, n=1(1.9) | N=66, n=5(7.6) | 0.224 |
| I don’t have access to providers for follow-up in my area. | N=55, n=11(20.0) | N=67, n=41(61.2) | <0.001 |
| There’s no financial incentive for my department. | N=52, n=4(7.7) | N=66, n=5(7.6) | 1.000 |
| It takes too much of my time. | N=53, n=6(11.3) | N=66, n=3(4.5) | 0.185 |
| I don’t have social work resources for screening and follow-up. | N=51, n=2(3.9) | N=67, n=14(20.9) | 0.008 |
| I don’t have training. | N=53, n=2(3.8) | N=67, n=12(17.9) | 0.017 |
| I don’t have buprenorphine in my ED. | N=54, n=11(20.4) | N=68, n=20(29.4) | 0.255 |
| I don’t want to assume medicolegal risk. | N=54, n=8(14.8) | N=67, n=13(19.4) | 0.508 |
| **Has ever prescribed** |            |           |         |
| Buprenorphine | N=12(20.0) | N=10(12.3) | <0.001 |
| Methadone | N=6(10.0) | N=14(17.3) |        |
| Both | N=36(60.0) | N=20(24.7) |     |
| Neither* | N=6(10.0) | N=37(45.7) |     |

*"Neither" was not an option on the survey
**All questions were not required to be answered to participate in this study.

MOUD, medication for opioid use disorder; ED, emergency department.
Western Journal of Emergency Medicine
Attitudes on Methadone Utilization in the ED

Heil et al.

(eg, unreliable transportation).36 Additionally, a protocol for methadone dosing in the ED setting should be created, and all emergency clinicians should be trained in its use. A protocol may be particularly useful to overcome clinicians’ hesitation concerning methadone use in the EM setting, given its interindividual variability in pharmacokinetics and potential for dose accumulation.

Despite ED-based efforts to increase post-discharge treatment engagement, patients face pre-existing access challenges to receipt of methadone in the community. Unlike buprenorphine, which may be prescribed by any waivered clinician, methadone can only be dispensed at federally certified opioid treatment programs that require supervised daily on-site medication dosing. These regulations limit access and increase the stigma associated with methadone treatment for OUD.37 COVID-19 era regulations relaxed the requirements for on-site methadone dosing, allowing up to 28 days of take-home doses with no evidence of negative outcomes.38,39 As states move to retain relaxed methadone regulations beyond the pandemic, establishing pathways for linkage to outpatient methadone treatment will be even more critical.40

Given that the perceived barriers to buprenorphine and methadone initiation in the ED were similar in this study, we postulate that stigma may play a role in EPs’ choice of MOUD. Previous studies seem to support this theory and demonstrate clear bias against patients receiving methadone and the clinics that provide methadone.20,42 To combat the stigma of methadone initiation in the ED, the same tools used to reduce the stigma of treating patients with a SUD in other healthcare settings can be used. Interventions include the following: integrating MOUD training into medical school curriculums; having specialty addiction consult services in hospitals; and providing continuing education that focuses on increasing awareness of the benefits of MOUD and highlights the barriers to OUD treatment.43-46

In addition to increased education and structural support, more research must be completed to assess methadone initiation in the ED. Research topics include conducting basic epidemiological studies on methadone initiation in the ED, establishing and evaluating an ED methadone initiation protocol, and monitoring the rate of successful linkage to follow-up care after methadone initiation in the ED. Additional studies on interventions to reduce the stigma of methadone and other MOUD treatments among EPs should also be conducted.

LIMITATIONS

This study had several limitations. The low response rate (18.4%) may have created some nonresponse bias in our results. This is similar to prior research reporting response rates of surveys distributed through a professional organization.47-49 Additionally, participants had to be members of ACEP to be invited to participate in this study. Response bias, specifically social desirability bias, could have led some EPs to select more supportive answers to adopting buprenorphine or methadone in the ED. Our study had a similar gender and race distribution of EPs in the US as reported elsewhere, although it is important to note that the majority of respondents identified as White males.50 Even though the demographic distribution of this study matches national patterns, they may not be generalizable to all EPs as the percentage of physicians who had completed their X-waiver in our study (38%) vastly differs from national estimates. A prior study reported that only 1% of EPs were X-waivered nationally.51 Another limitation of the study is that there was no way to control for multiple respondents from the same institution because this study’s survey and EMPRN did not collect institution-specific data. Lastly, it is important to note that our research team assumed that the EP had not ordered either MOUD if the participant did not answer the question of whether they had ordered buprenorphine or methadone while working in the ED.

CONCLUSION

Our cross-sectional study demonstrates that, despite more than 50 years of data demonstrating methadone’s efficacy, emergency physicians are not comfortable using methadone for patients with opioid use disorder. Buprenorphine has been embraced by EPs, largely as a result of ongoing local, regional, and national education efforts, as well as widely publicized and distributed statements by influential professional organizations.12,17,52 Similar efforts should now be undertaken to educate and support emergency physicians to increase methadone utilization and decrease the stigma frequently associated with this life-saving medication.

Address for Correspondence: Jessica Heil, MS, Cooper University Health Care, Cooper Research Institute, 102 17th St SE, Washington, DC 20003. Email: heil-jessica1@cooperhealth.edu.

Conflicts of Interest: By the WestJEM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. No author has professional or financial relationships with any companies that are relevant to this study. There are no conflicts of interest or sources of funding to declare.

Copyright: © 2022 Heil et al. This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) License. See: http://creativecommons.org/licenses/by/4.0/

REFERENCES

1. Mattson CL, Tanz LJ, Quinn K, et al. Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019. MMWR Morb Mortal Wkly Rep. 2021;70(6):202-7.
2. Ahmad FB, Rossen LM, Spencer MR, et al. Provisional drug
heil et al.

Articles in Press 9 Western Journal of Emergency Medicine

overdose death counts. National Center for Health Statistics. 2021. Available at: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed May 5, 2021.

3. Davenport S, Weaver A, Caverly M. Economic impact of non-medical opioid use in the United States: Annual estimates and projections for 2015 through 2019. 2019. Available at: https://www.ssa.org/globalassets/assets/files/research-report/2019/econ-impact-non-medical-opioid-use.pdf. Accessed on January 25, 2021.

4. SAMHSA. Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health 2020. 2020. Available at: https://www.samhsa.gov/data/sites/default/files/rpt29393/2019NSDUHFFPDPDFWHTML/2019NSDUHFFR1PDFW090120.pdf. Accessed May 5, 2021.

5. Salzman M, Jones CW, Rafeq R, et al. Epidemiology of opioid-related visits to US emergency departments, 1999-2013: A retrospective study from the NHAMS (National Hospital Ambulatory Medical Care Survey). Am J Emerg Med. 2020;38(1):23-7.

6. Weiner SG, Baker O, Bernson D, et al. One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. Ann Emerg Med. 2020;75(1):13-7.

7. SAMHSA. Use of medication-assisted treatment in emergency departments (No. PEP21-PL-Guide-5). 2021. Available at: https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/pep21-pl-guide-5.pdf. Accessed January 25 2021.

8. Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73(5):481-7.

9. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

10. Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-45.

11. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane database of systematic reviews. 2014;(2):CD002207.

12. Strayer RJ, Hawk K, Hayes BD, et al. Management of opioid use disorder in the emergency department: a white paper prepared for the American Academy of Emergency Medicine. J Emerg Med. 2020;58(3):522-46.

13. D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636-44.

14. Zuckerman M, Kelly T, Heard K, et al. Physician attitudes on buprenorphine induction in the emergency department: results from a multisite survey. Clin Toxicol (Phila). 2021;59(4):279-85.

15. Duber HC, Barata IA, Ciocê-Pêna E, et al. Identification, management, and transition of care for patients with opioid use disorder in the emergency department. Ann Emerg Med. 2018;72(4):420-31.

16. Martin A, Mitchell A, Wakeman S, et al. Emergency department treatment of opioid addiction: an opportunity to lead. Acad Emerg Med. 2018;25(5):601-4.

17. Hawk K, Hoppe J, Ketcham E, et al. Consensus recommendations on the treatment of opioid use disorder in the emergency department. Ann Emerg Med. 2021;78(3):534-42.

18. SAMHSA. Medications for opioid use disorder TIP 63 treatment improvement protocol for healthcare and addiction professionals, policymakers, patients, and families. 2018. Available at: https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Diorder-FullDocument/PEP21-02-01-002. Accessed January 25, 2021.

19. SAMHSA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2019. Data on Substance Abuse Treatment Facilities. 2020. Available at: https://www.samhsa.gov/data/sites/default/files/reports/rpt35313/2020_NSSATS_FINAL.pdf. Accessed January 25, 2021.

20. Cioe K, Biondi BE, Easley R, et al. A systematic review of patients’ and providers’ perspectives of medications for treatment of opioid use disorder. J Subst Abuse Treat. 2020:108146.

21. Su MK, Lopez JH, Cossa A, et al. Low dose intramuscular methadone for acute mild to moderate opioid withdrawal syndrome. Am J Emerg Med. 2018;36(11):1951-6.

22. ASAM. The American Society of Addiction Medicine National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 focused update. J Addict Med. 2020;14(25):1-91.

23. Mackey K, Veazie S, Anderson J, et al. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35(Suppl 3):1-10.

24. Clemans-Cope L, Benatar S, Epstein M, et al. Potential cost savings associated with providing screening, brief intervention, and referral to treatment for substance use disorder in emergency departments. 2018. Available at: https://www.urban.org/sites/default/files/publication/98535/2001854_-_potential_cost_savings_associated_with_sbirt_in_emergency_departments_rapid_review_finalized_2.pdf. Accessed January 25, 2021.

25. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622-e1920622.

26. Mannelli P, S Peindl K, Lee T, et al. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5(1):52-63.

27. Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39(1):51-7.

28. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA. 1965;193(8):646-50.

29. Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183-8.

30. Varshneya NB, Thakrar AP, Hobelmann JG, et al. Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl. J Addict Med. 2021.

31. Silverstein SM, Danilaultyte R, Martins SS, et al. “Everything is not right anymore”: Buprenorphine experiences in an era of illicit fentanyl. Int J Drug Policy. 2019;74:76-83.

32. Hawk KF, D’Onofrio G, Chawarski MC, et al. Barriers and facilitators
to clinician readiness to provide emergency department–initiated buprenorphine. *JAMA Netw Open*. 2020;3(5):e204561-e204561.

33. Rhee TG, D’Onofrio G, Fiellin DA. Trends in the use of buprenorphine in US emergency departments, 2002-2017. *JAMA Netw Open*. 2020;3(10):e2021209-e2021209.

34. Martin A, Butler K, Chavez T, et al. Beyond buprenorphine: models of follow-up care for patients with opioid use disorder in the ED. *West J Emerg Med*. 2020;21(6):257-63.

35. Barnett PG, Masson CL, Sorenson JL, et al. Linking opioid-dependent hospital patients to drug treatment: health care and costs 6 months after randomization. *Addiction*. 2006;101(12):1797-804.

36. Snyder H, Kalmin MM, Moulin A, et al. Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA bridge program. *Ann Emerg Med*. 2021;78(6):759-72.

37. Tsai AC, Kiang MV, Barnett ML, et al. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. *PLoS Med*. 2019;16(11):e1002969.

38. Figgatt MC, Salazar Z, Day E, et al. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. *J Subst Abuse Treat*. 2021;123:108276.

39. Amram O, Amiri S, Panwala V, et al. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. *Am J Drug Alcohol Abuse*. 2021;47(6):1-8.

40. SAMHSA. Opioid Treatment Program (OTP) Guidance. 2020. Available at: https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf. Accessed January 25, 2021.

41. Opioid Treatment Access Act of 2022, H.R.6279, House of Representatives, 117th session (Norcross D 2021).

42. Kennedy-Hendricks A, Barry CL, et al. Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians. *Drug Alcohol Depend*. 2020;216:108217.

43. Kennedy-Hendricks A, McGinty EE, Barry CL. Effects of competing narratives on public perceptions of opioid pain reliever addiction during pregnancy. *J Health Polit Policy Law*. 2016;41(5):873-916.

44. Livingston JD, Milne T, Fang ML, et al. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. *Addiction*. 2012;107(1):39-50.

45. Wakeman SE, Kanter GP, Donelan K. Institutional substance use disorder intervention improves general internist preparedness, attitudes, and clinical practice. *J Addict Med*. 2017;11(4):308-14.

46. McGinty E, Pescosolido B, Kennedy-Hendricks A, et al. Communication strategies to counter stigma and improve mental illness and substance use disorder policy. *Psychiatr Serv*. 2018;69(2):136-46.

47. Nguyen J, Liu A, McKenney M, et al. Impacts and challenges of the COVID-19 pandemic on emergency medicine physicians in the United States. *Am J Emerg Med*. 2021;48:38-47.

48. Abir M, Moore M, Chamberlin M, et al. Using timely survey-based information networks to collect data on best practices for public health emergency preparedness and response: illustrative case from the American College of Emergency Physicians’ Ebola surveys. *Disaster Med Public Health Prep*. 2016;10(4):681-90.

49. Brody A, Twiner M, Kumar A, et al. Survey of emergency physician approaches to management of asymptomatic hypertension. *Journal Clin Hypertens (Greenwich)*. 2017;19(3):265-9.

50. AAMC. Diversity in medicine: facts and figures 2019. 2019. Available at: https://www.aamc.org/data-reports/workforce/report/diversity-medicine-facts-and-figures-2019. Accessed August 1, 2021.

51. Rosenblatt RA, Andrilla CHA, Catlin M, et al. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. *Ann of Fam Med*. 2015;13(1):23-6.

52. Wax PM, Stolbach AI, Schwarz ES, et al. ACMT position statement: buprenorphine administration in the emergency department. *J Med Toxicol*. 2019;15(3):215-6.